Double-blind, randomized, placebo-controlled, multi center trial to evaluate the efficacy and safety of levetiracetam as adjunctive treatment in adult Japanese epileptic subjects with partial onset seizures...
Date First Received: January 14, 2008
Last Updated: March 7, 2008
Verified by: UCB, March 2008
Clinical Trial Phase: Phase 2 | Start Date: January 2001
Overall Status: Completed
Estimated Enrollment: 216
Brief Summary
Official Title: “Bridging Study of L059(Levetiracetam) in Patients With Epilepsy by Double Blind Method”
Condition Keyword(s):
Intervention(s):
Double-blind, randomized, placebo-controlled, multi center trial to evaluate the efficacy and safety of levetiracetam as adjunctive treatment in adult Japanese epileptic subjects with partial onset seizures.
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Study Primary Completion Date: July 2003
Intervention(s) in this Clinical Trial
- Drug: Levetiracetam
Outcome Measures for this Clinical Trial
Primary Measures
- partial onset siezure frequency per week
- Time Frame: collection of seizure count throughout the whole study (baseline and treatment periods)
- Time Frame: collection of seizure count throughout the whole study (baseline and treatment periods)
Secondary Measures
- safety and tolerability
- Time Frame: safety and tolerability data were collected throughout the study period
- Time Frame: safety and tolerability data were collected throughout the study period
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- simple and/or complex partial seizures with or without secondary generalization, and first partial seizure >= 2 years before selection visit;
- seizures classifiable according to the ILAE classification;
- minimum of 12 partial seizures per 12 weeks with a minimum of two partial seizures per 4 weeks from the selection visit to the end of the baseline period ;
- exposed to two or more standard AEDs;
- taking up to three of the standard AEDs, at the initiation of the trial.
Exclusion Criteria:
- medication influencing the CNS, except for medication taken for antiepileptic treatment;
- partial seizures uncountable due to clustering, including status epilepticus, during the 3 months prior to the selection visit;
- history of cerebrovascular disease including transient ischemic attack (TIA) and progressive cerebral disorder or progressive neurological disorder;
- presence or history of any clinically significant allergic condition and complication or history of significant alcohol abuse or drug abuse in the past.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 16 Years
Maximum Age for this Clinical Trial: 65 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: UCB
Overall Clinical Trial Officials and Contacts
UCB Clinical Trial Call Center Study Director +1 877 822 9493 (UCB)
Additional Information
Information obtained from ClinicalTrials.gov on August 29, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00600509
Study ID Number: N165
ClinicalTrials.gov Identifier: NCT00600509
Health Authority: Japan: Ministry of Health, Labor and Welfare
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.